Project Grant R03DK139233
- This $2,842,245 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to elucidate the role of intestinal epithelial cell (IEC) injury pathways in governing anti-TNF therapy effectiveness for ulcerative colitis. The project aims to identify predictive biomarkers in formalin-fixed, paraffin-embedded (FFPE) patient biopsies that...
- This Project Grant award of $234,000 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at the University of Colorado-Denver to investigate the role of the Aiolos transcriptional regulator in the pathogenesis of inflammatory bowel disease. The researchers aim to utilize CRISPR-Cas9 genome editing to examine how Aiolos regulates T cell...
- This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research focused on understanding the mechanisms that regulate lipid flux in cells and animals, and how crosstalk between gut immune cells and the absorptive epithelium impacts metabolic disease. The $761,399 award, effective September 1, 2025 through June 30, 2030, will...
- This federal Project Grant award of $580,568, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research on the role of the CD45 tyrosine phosphatase in regulating neutrophil function and intestinal inflammation. The research aims to elucidate the effects of neutrophil-specific loss of CD45 on intestinal inflammation and repair, as well as how CD45...
- This federal Project Grant award of $228,948 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at Weill Medical College of Cornell University to investigate the role of the neuropeptide adrenomedullin 2 (ADM2) in regulating intestinal inflammation and promoting tissue protection in inflammatory bowel diseases (IBD) such as ulcerative...
- This federal Project Grant award of $458,047.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to understand how extracellular vesicles (EVs) from intestinal epithelial cells (enterocytes) mediate cell-to-cell communication and function as effectors of inflammation in inflammatory bowel disease (IBD). Specific objectives include identifying...
- This federal Project Grant award of $358,039 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is supporting research by Nous Biosciences Inc. to evaluate a combination therapy of dolcanatide (a guanylate cyclase-C agonist) and atiprimod (a JAK-STAT inhibitor) for the treatment of murine colitis. The research aims to advance understanding of the pathogenesis of...
- This $164,188 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The 5-year grant supports training and research at the University of Washington to study the role of intestinal chondroitin sulfate glycosaminoglycans in inflammatory bowel disease. The research aims to determine how changes in the composition of these gut matrix...
- This federal Project Grant award of $2,325,005 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) will support research at Mayo Clinic to investigate the molecular mechanisms underlying the imbalance between autophagy and extracellular vesicle secretion pathways in pancreatic beta cells under diabetogenic stress conditions. The research aims to improve understanding of type 2 diabetes pathogenesis...
- This federal Project Grant award of $465,444.00, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate how commensal fungi in the gut can promote intestinal wound repair. The research aims to mechanistically understand how fungi modulate epithelial cells and fibroblasts to enhance crypt regeneration, with a focus on identifying the...
This federal Project Grant award of $242,100.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will support research by Mayo Clinic to investigate the role of sphingolipid metabolism in regulating regulatory T cell function and intestinal homeostasis, with the goal of developing new therapeutic strategies for inflammatory bowel disease. The project will run from September 15, 2025 to August 31, 2027 and involves unbiased metabolomics analysis, in vitro studies, and experimental mouse models to elucidate the importance of specific lipid species in maintaining the immunosuppressive phenotype of regulatory T cells during chronic intestinal inflammation. The findings from this project will contribute preliminary data for a planned R01 application to further explore the molecular mechanisms linking lipid metabolism and regulatory T cell function in inflammatory bowel disease.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $242.1k | 9/4/25 |